Purpose: To describe A1c changes and characteristics of patients with type 2 diabetes mellitus (T2DM) initiating oral semaglutide (sema) , by baseline A1c ≥9% and <9%.

Methods: Retrospective analysis using medical and pharmacy claims data from 11/01/2018-12/31/2020 from commercial and Medicare Advantage with Part D enrollees, aged 18+. Patients had ≥1 claim for oral sema (first claim=index date) , ≥1 T2DM diagnosis, continuous enrollment for 12 months before and including index (baseline) , and 6 months post-index (follow-up) , pregnant females excluded. Results were stratified by patient’s last baseline A1c (< or ≥9%) .

Results: Patients initiating oral sema who had ≥1 baseline A1c (n=994) had a mean age of 59 years, 50.4% were male, and 63.1% had commercial coverage. Among patients with baseline and follow-up A1c values (n=652) , mean A1c change was -0.8% (1.49) . Among a subset with ≥90 days of continuous oral sema treatment and ≥1 A1c after ≥90 days of treatment (n=200) , the A1c ≥9% group had a mean A1c change of -2.7% (2.1) . While half of index treatments were prescribed by primary care and internal medicine providers (50.6% overall) , a higher percentage of patients with A1c <9% had oral sema prescribed by an endocrinologist (24.4% vs. 16.1%; p=0.006) .

Conclusions: Results suggest that oral sema is an effective T2DM treatment in the real-world, especially among patients with A1c values ≥9% prior to treatment initiation. Patients with T2DM in this population are more often prescribed oral sema by primary care physicians than endocrinologists.


M. S. Frazer: None. C. Swift: Employee; Novo Nordisk. M. Leszko: None. A. Sargent: None. E. Buysman: None. S. B. Alvarez: Employee; Novo Nordisk, UnitedHealth Group. J. Noone: Employee; Novo Nordisk. M. Guevarra: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.